One stock that might be an intriguing choice for investors right now is BlackBerry LimitedBBRY. This is because this security in the Wireless Non-US space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Wireless Non-US space as it currently has a Zacks Industry Rank of 69 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
Meanwhile, BlackBerry is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.
BlackBerry Limited Price and Consensus
BlackBerry Limited Price and Consensus | BlackBerry Limited Quote
In fact, over the past month, current quarter estimates have remained unchanged at a loss of 1 penny, while current year estimates have risen from a loss of 5 cents per share to a loss of 4 cents per share. This has helped BBRY to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
So, if you are looking for a decent pick in a strong industry, consider BlackBerry. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.
5 Trades Could Profit “Big-League” from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington’s changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.